LVW Advisors LLC Has $1.05 Million Stake in AstraZeneca PLC (NASDAQ:AZN)

LVW Advisors LLC trimmed its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 8.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 15,962 shares of the company’s stock after selling 1,564 shares during the quarter. LVW Advisors LLC’s holdings in AstraZeneca were worth $1,046,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Martin Investment Management LLC boosted its holdings in AstraZeneca by 2.8% during the third quarter. Martin Investment Management LLC now owns 284,204 shares of the company’s stock valued at $22,571,000 after acquiring an additional 7,615 shares during the period. Nordea Investment Management AB bought a new stake in AstraZeneca during the fourth quarter valued at about $754,000. Integrated Advisors Network LLC boosted its holdings in AstraZeneca by 46.6% during the third quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company’s stock valued at $3,398,000 after acquiring an additional 13,860 shares during the period. Creative Planning boosted its holdings in AstraZeneca by 8.0% during the third quarter. Creative Planning now owns 224,751 shares of the company’s stock valued at $17,510,000 after acquiring an additional 16,692 shares during the period. Finally, Soros Fund Management LLC boosted its holdings in AstraZeneca by 8.2% during the third quarter. Soros Fund Management LLC now owns 2,652,771 shares of the company’s stock valued at $206,677,000 after acquiring an additional 201,233 shares during the period. 20.35% of the stock is owned by institutional investors and hedge funds.

AstraZeneca Stock Down 0.5 %

NASDAQ AZN opened at $66.60 on Monday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93. The firm has a 50-day simple moving average of $66.11 and a 200 day simple moving average of $74.48. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $87.68. The stock has a market cap of $206.50 billion, a PE ratio of 31.87, a PEG ratio of 1.05 and a beta of 0.46.

AstraZeneca (NASDAQ:AZN) last released its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business had revenue of $13.57 billion during the quarter, compared to analysts’ expectations of $13.08 billion. During the same quarter last year, the company earned $0.87 earnings per share. The firm’s revenue was up 18.0% on a year-over-year basis. On average, research analysts forecast that AstraZeneca PLC will post 4.11 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on AZN shares. UBS Group upgraded shares of AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, AstraZeneca currently has an average rating of “Buy” and an average target price of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.